Efficiency of GemCap + mitotane in platinum and mitotane resistant adrenocortical carcinoma

#3918

Introduction: Gemcitabine, metronomic capecitabine and mitotane (M) combination (GemCap + M) is the most investigated and widely used regimen in 2nd and subsequent lines therapy of advanced adrenocortical cancer (ACC). In the largest retrospective study (N=145) only 28% of patients (pts) reached therapeutic concentration of mitotane (M), which translated into a significant improvement in the median progression free survival (PFS).

Aim(s): Studying the effectiveness of chemotherapy GemCap+M in patients who have reached therapeutic concentrations of M.

Materials and methods: This retrospective study included patients over 18 years of age with histologically confirmed ACC and disease progression after completion of platinum-containing therapy and platinum-free interval <6 months. All pts had reached therapeutic concentration of M in previous lines of therapy. Prescribed ChT regimen was gemcitabine 800 mg / m2 for days 1, 8 and capecitabine 1000 mg / m2 orally 2 times at days 1–14 of the 21-day cycle + M. The study assessed efficacy - response rate (ORR), PFS, overall survival (OS) and tolerability of this regimen.

Conference:

Presenting Author: Zhulikov Y

Authors: Zhulikov Y, Kovalenko E, Bokhyan V, Evdokimova E, Khoroshilov M,

Keywords: adrenocortical cancer, gemcitabine, capecitabine, GemCap, mitotane,